| Literature DB >> 16997553 |
Igor Nudelman1, Annie Rebibo-Sabbah, Dalia Shallom-Shezifi, Mariana Hainrichson, Ido Stahl, Tamar Ben-Yosef, Timor Baasov.
Abstract
A series of new derivatives of the clinically used aminoglycoside antibiotic paromomycin were designed, synthesized, and their ability to read-through premature stop codon mutations was examined in both in vitro translation system and ex vivo mammalian cultured cells. One of these structures, a pseudo-trisaccharide derivative, showed notably higher stop codon read-through activity in cultured cells compared to those of paromomycin and gentamicin.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16997553 DOI： 10.1016/j.bmcl.2006.09.013
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823